Zacks Research Has Pessimistic View of GSK Q4 Earnings

GSK plc (NYSE:GSK) – Stock analysts at Zacks Research reduced their Q4 2024 earnings per share estimates for shares of GSK in a research report issued on Tuesday, November 19th. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will earn $0.63 per share for the quarter, down from their prior estimate of $0.76. The consensus estimate for GSK’s current full-year earnings is $4.03 per share. Zacks Research also issued estimates for GSK’s Q4 2025 earnings at $0.84 EPS, FY2025 earnings at $4.34 EPS, Q2 2026 earnings at $1.13 EPS and FY2026 earnings at $4.90 EPS.

GSK has been the topic of a number of other research reports. Argus raised GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and decreased their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Barclays raised shares of GSK to a “hold” rating in a research note on Tuesday, August 27th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Seven investment analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Up 0.8 %

Shares of GSK stock opened at $33.96 on Thursday. GSK has a 12-month low of $32.83 and a 12-month high of $45.92. The firm has a market capitalization of $70.37 billion, a PE ratio of 22.05, a price-to-earnings-growth ratio of 1.29 and a beta of 0.66. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The stock’s fifty day moving average is $38.09 and its 200-day moving average is $40.37.

Institutional Investors Weigh In On GSK

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Eastern Bank bought a new stake in GSK in the third quarter valued at about $26,000. Sunbelt Securities Inc. grew its stake in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Concord Wealth Partners increased its holdings in shares of GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 547 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new position in GSK in the 2nd quarter worth approximately $37,000. Finally, Fortitude Family Office LLC acquired a new position in GSK during the 3rd quarter worth $42,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Insider Transactions at GSK

In other news, major shareholder Plc Gsk purchased 2,791,930 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was bought at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the acquisition, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. The trade was a 19.97 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.00% of the stock is currently owned by corporate insiders.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be given a $0.3928 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.63%. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s payout ratio is currently 98.70%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.